Future studies are needed to dismantle the role of endogenous MIF in AD to entail the use of specific MIF inhibitors and exogenously administered MIF in transgenic models of AD, as well as the dosing of RedMIF vs. oxMIF in CSF and periphery of AD patients at different stages of the disease. Here, MIF is linked to Alzheimer disease.